Sign in
Taking peoplePhase 3

Safety and clinical parameter assessment of self-infusion therapy with Prolastin® in patients with severe AATD

Key facts

Who runs it
Grifols S.A.
Where
Germany7 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
33 people, planned
Started
1 Jul 2025
Expected to end
1 Jul 2027
Type of study
Interventional
Record updated
6 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Signed written informed consent obtained prior to any study-related procedure
  • At least 18 years of age
  • Able to understand and read German at a level sufficient to comprehend patient documents, including the informed consent, instruction materials and questionnaires. Note: Assistance for any required writing tasks can be provided by the caregiver
  • A documented diagnosis of severe Alpha-1 Antitrypsin Deficiency
  • Treatment with Prolastin® for at least 3 months with documented good treatment tolerability
  • Ability and willingness to learn self-infusion and perform infusions at home or being accompanied by a third person (i.e. caregiver), who has the ability and willingness to learn and perform infusions without HCP supervision (after appropriate training). Note: For patients requiring a caregiver, the availability of a suitable caregiver must be ensured in order to be eligible for inclusion. For patients who perform the self-infusion themselves, the availability of an emergency contact, i.e. a person who is willing and able to be present and monitor the patient during every self-infusion throughout the main study period, must be ensured in order to be eligible for inclusion
  • Having access to and being able to use (incl. reading and typing) a functional electronic device that enables phone calls and video calls (for remote calls from the study site or home-care study nurses) and access to an internet browser (for completion of the questionnaires)
  • Suitable veins for venepuncture, according to the investigator’s discretion
  • Life expectancy of over 3 years

Who cannot take part

  • Occurrence of serious adverse drug reactions due to Prolastin® infusion in the last 3 months prior to V0
  • Patients who have undergone lung transplantation
  • Participation in another clinical study with investigational medicinal product within the last 3 months prior to baseline visit or simultaneous participation in another clinical study
  • Contraindications as listed in the current SmPC: a) Individuals with selective immunoglobulin A (IgA) deficiency b) Known hypersensitivity against human Alpha-1 Proteinase Inhibitor or to any of the other ingredients in the formulation or component of the container
  • Patients with psychiatric illnesses, imprisoned persons, persons admitted to nursing homes, persons under legal guardianship and persons not able to express their consent (e.g. due to mental impairment)
  • Current smokers
  • Patients with venous access via port
  • Breastfeeding or pregnant women

This trial is currently available in Germany.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the safety of self-infusion therapy with Prolastin® in patients with severe AATD

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Safety and clinical parameter assessment of a 12-week home self-infusion therapy with Prolastin® in patients with severe alpha-1-antitrypsin (AATD) deficiency. The “Sunshine Study”
Record updated
6 October 2026